Increasing Sensitivity in Patient‐Reported <scp>MDS</scp>‐<scp>UPDRS</scp> Items for Predicting Medication Initiation in Early <scp>PD</scp>

A six-item "Baseline Outcome Voice" version of patient-reported MDS-UPDRS items significantly increases the sensitivity of predicting the key future clinical outcome of starting dopaminergic treatment in early PD. This study also demonstrates how IRT modeling can provide information useful to refining existing measures to identify the most sensitive combination of items honoring the voice of the patient in determining key clinically pertinent decisions. Further research is needed to validate these findings in underrepresented populations.

Authors

Institutions

Publication Details

Journal
Movement Disorders Clinical Practice
Published
2024-10-18
DOI
https://doi.org/10.1002/mdc3.14229
Citations
4
Primary Topic
Pharmaceutical studies and practices
Type
article
Field-Weighted Citation Impact
4.44

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Increasing Sensitivity in Patient‐Reported MDS‐UPDRS Items for Predicting Medication Initiation in Early PD

Haotian Zou, Christopher G. Goetz, Tiago Mestre, Glenn T. Stebbins et al.
4 citations
Movement Disorders Clinical Practice
Pharmaceutical studies and practices
4.44
article

Increasing Sensitivity in Patient‐Reported MDS‐UPDRS Items for Predicting Medication Initiation in Early PD

Haotian Zou, Christopher G. Goetz, Tiago Mestre, Glenn T. Stebbins, Sheng Luo
article en
4 citations

Abstract

A six-item "Baseline Outcome Voice" version of patient-reported MDS-UPDRS items significantly increases the sensitivity of predicting the key future clinical outcome of starting dopaminergic treatment in early PD. This study also demonstrates how IRT modeling can provide information useful to refining existing measures to identify the most sensitive combination of items honoring the voice of the patient in determining key clinically pertinent decisions. Further research is needed to validate these findings in underrepresented populations.

Movement Disorders Clinical PracticeVol. 12(2)
Rush University Medical Center (US), University of Ottawa (CA), Duke University (US), Ottawa Hospital (CA), MIND Research Institute (US), Ottawa Hospital Research Institute (CA), uOttawa Brain and Mind Research Institute
U.S. Department of Defense, Michael J. Fox Foundation for Parkinson's Research, Alzheimer's Association, Pfizer, Biogen, CHDI Foundation, Cleveland Clinic, Cleveland Clinic Foundation, International Parkinson and Movement Disorder Society, University of Ottawa, Rush University, Fondation Brain Canada, Ottawa Hospital Research Institute, Sunovion, Parkinson's Foundation, Neurocrine Biosciences, Adamas Pharmaceuticals, Physicians' Services Incorporated Foundation, National Institute for Health and Care Research, Parkinson's UK, University of Oxford, European Commission, Parkinson Canada, National Institutes of Health, Parkinsonfonden, Canadian Institutes of Health Research, National Institute on Aging, NIH Clinical Center, Dystonia Coalition
Reduced inequalities
Openalex Percentile: Top 6%
Pharmaceutical studies and practices
4.44
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.